Dress up or dress down and join the members of Krewe de Pink on Zoom - Saturday, October 24, 7 - 11 PM - for the VIRTUAL 2020 Krewe de Pink Prom, benefiting Tulane Cancer Center's Breast Cancer Research Program.
"We invite the community to come have a great time raising money to continue the fight against breast cancer," said Dawn Arevalo, Krewe de Pink Prom event chair. "Our researchers at Tulane can’t do it alone. They need our help to raise money so they can work on finding a cure. The VIRTUAL Krewe de Pink Prom will be a night filled with fun, live from the safety of everyone's own home! We hope people come for a bit or stay the whole time, and invite their friends from around the world to join in and party with them."
The virtual event will include raffles, a silent auction, friendly competitions, and the annual naming of prom king and queen! Tickets are $25 each, and only one ticket is needed per viewing device, regardless of the number of people participating from the same household. To register - or start bidding on silent auction items! - visit the event webpage at: https://www.accelevents.com/e/KrewedePinkProm2020
Krewe de Pink is a New Orleans-based 501(c)(3) organization made up of concerned and passionate individuals who have all been impacted by the effects of breast cancer and inspired by survivors. The organization produces three fundraising events each year -- the Pink Bra Run, the Krewe de Pink Prom, and Death by Chocolate-Not Breast Cancer -- and has raised more than $100,000 for breast cancer research since 2011.
Proceeds from Krewe de Pink fundraisers benefit the laboratories of Bridgette Collins-Burow, MD, PhD, associate professor of medicine (top), and Matthew Burow, PhD, assistant professor of medicine (bottom), whose teams focus on triple negative breast cancer (TNBC).
Approximately 10-15% of diagnosed breast cancers are triple negative, which means they do not have any of the receptors commonly found in breast cancer.
"Specifically, it's deﬁned by a lack of estrogen receptor, progesterone receptor, and Her2/Neu over‐expression," said Dr. Collins-Burow. "Therefore, patients with this disease have not beneﬁted from advances in therapeutics that target these receptors."
TNBC is more prevalent in African American women, occurs more frequently in younger patients, and has an aggressive clinical history, evidenced by its rapid progression to a metastatic phenotype as well as shorter life expectancy for patients.
"Therefore, it's critical to identify novel targets for treating this disease," said Dr. Collins-Burow. "And we couldn't be more grateful to the members of Krewe de Pink who work so hard to raise important funds to support our work."
For more information on the Collins-Burow/Burow lab, please visit https://burowlab.tulane.edu/lab-members/. For more information on Krewe de Pink and its annual events, please visit https://www.krewedepink.org/.
For more information on Tulane Cancer Center news and events, please contact:
Melanie N. Cross
Manager of Communications
Tulane Cancer Center
1430 Tulane Ave., Box 8668
New Orleans, LA 70112